Safety and Immunogenicity of a PD-1-Enhanced HIV-1 Therapeutic DNA Vaccine: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Trial in People With HIV-1 on Antiretroviral Therapy

Authors:

Abstract
Background: Therapeutic vaccines represent a potential strategy for HIV-1 control without antiretroviral therapy (ART). We report a first-in-human study on ICVAX™, a PD-1-enhanced HIV-1 therapeutic DNA vaccine. Methods: This NMPA-approved, randomized, double-blind, placebo-controlled, dose-escalation phase I trial (NCT06253533) was conducted at Shenzhen Third People's Hospital, China. Adults with HIV-1 aged 18–50 years on ART were sequentially allocated to 1, 2, or 4 mg dose groups of 15, each randomized 12:3 to ICVAX or placebo. Participants received intramuscular injections with electroporation at Weeks 0, 4, 8, 12, and 36. Primary safety, secondary immunological, and exploratory virological outcomes were recorded. Results: All 45 participants completed the trial, with 12 per ICVAX cohort and 9 in pooled Placebo. Treatment-related adverse events occurred in 100% of placebo and 83.3% of ICVAX recipients, all mild and transient, predominantly local reactions. A ≥2-fold increase of peak ELISpot T-cell responses over baseline was achieved by 75%, 75%, and 58.3% of low-dose, mid-dose, and high-dose recipients, versus 33.3% for Placebo. ICVAX recipients also showed low-frequency Gag-specific T cells expressing CD107a and/or effector cytokines. Conclusions: ICVAX was well-tolerated and elicited robust antigen-specific T-cell responses in ART-suppressed people with HIV-1. Its efficacy will be assessed in future studies.
Funding Information
  • Immuno Cure Group
  • Clinical Translational Catalyst programme of Hong Kong Science & Technology Parks Corporation
  • Hong Kong Research Grants Council Theme-Based Research Scheme (T11-706/18-N)
  • Hong Kong Research Grants Council Theme-Based Research Scheme (T11-702/24-N)
  • Shenzhen Science and Technology Innovation Program (JSYJ20240813102007011)
  • National Key Research and Development Program of China (2021YFC2301900)
  • National Key Research and Development Program of China (2023YFC2308300)
  • Shenzhen Clinical Research Centre for Emerging Infectious Diseases (LCYSSQ20220823091203007)
  • Shenzhen High-level Hospital Construction Fund
  • Immuno Cure Group

This publication has 46 references indexed in Scilit: